Eterna Therapeutics Inc (ERNA) Noticias

Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer

CAMBRIDGE, Mass., Jan. 14, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell...

Form 8-K - Current report

Eterna Therapeutics Announces Appointment of Dr. Elena Ratner to Board of Directors

CAMBRIDGE, Mass., Jan. 09, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), a leader in cell...

Eterna Therapeutics Launches Research to Evaluate its Lead Induced Mesenchymal Stem Cell Therapy Candidate’s (ERNA-101) Ability to Induce and Modulate Antitumor Immunity in Ovarian Cancer and Breast Cancer Models

CAMBRIDGE, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA) today announced it...

Eterna Therapeutics Announces Up to $1 Million Stock Repurchase Program

CAMBRIDGE, Mass., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics, Inc. (Nasdaq: ERNA), a leader in...

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form 424B3 - Prospectus [Rule 424(b)(3)]

Form EFFECT - Notice of Effectiveness

Eterna Therapeutics Regains Compliance with NASDAQ for Continued Listing

CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the...

Form D - Notice of Exempt Offering of Securities

Form D - Notice of Exempt Offering of Securities

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form S-1 - General form for registration of securities under the Securities Act of 1933

Form 4 - Statement of changes in beneficial ownership of securities